Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Subscribe To Our Newsletter & Stay Updated
